Alpelisib-Piqray Lung Cancer

Alpelisib (Alpelisib)-Piqray is a proline or derivative used as an anti-tumor agent. It is formulated as film-coated tablets for the oral route of administration. Apelvis is indicated in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor-positive and HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. As for the treatment of lung cancer, there is currently no evidence to officially approve the use of Apelvis.

Apelix will not prolong the QTcF intervalPatients taking Apelvis will obtain dose-dependent benefits from the treatment, with a daily dose of 200 mg having a 51% advantage over the 100 mg dose, and a once-daily dose of 300 mg having a 22% advantage over the twice-daily 150 mg dose. This suggests that patients requiring lower doses may benefit from twice daily dosing. Activation of the PI3K pathway is often associated with endocrine resistance and poor prognosis in cancer. Recently, the synergistic effect of apelvis in combination with targeted drugs has been widely reported in PIK3CA-mutated cancer cells, such as breast cancer, head and neck squamous cell carcinoma (HNSCC), cervical cancer, liver cancer, pancreatic cancer, and lung cancer. But in the treatment of lung cancer, doctors usually choose appropriate treatment options, such as surgical resection, radiotherapy, chemotherapy, targeted therapy, etc., based on individualized circumstances and clinical guidelines.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.